Investigational drug · Phase 3
XNW5004
Also called: EZH2i
Not approved by FDA. In 7 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Relapsed/Refractory Peripheral T Cell Lymphoma, Advanced Prostate Cancer, Follicular Lymphoma, Grade 1.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
7
6 still active
All registered trials
8
Any phase or sponsor naming "XNW5004"
First trial start
2021
Aug 3, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "XNW5004", any sponsor or status.
Conditions studied
As listed on its trial records.
- Relapsed/Refractory Peripheral T Cell Lymphoma
- Advanced Prostate Cancer
- Follicular Lymphoma, Grade 1
- Follicular Lymphoma, Grade 2
- Follicular Lymphoma, Grade 3
- Follicular Lymphoma Grade 3A
- Metastatic Castrate-Resistant Prostate Cancer
- mCRPC (Metastatic Castration-resistant Prostate Cancer)
- Non-hodgkin Lymphoma
- Peripheral T-cell Lymphoma
Approved drugs for the same conditions: Prostate cancer · Lymphoma (non-Hodgkin) · Hodgkin lymphoma · Oncology · Hematology and blood cancers · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "XNW5004" as an intervention, largest first.
Evopoint Biosciences Inc.Industry
NCT06702995 · 307 participants (planned) · Start Apr 19, 2023 · Primary completion Jul 13, 2027
Drug: XNW5004; enzalutamide · For: Metastatic Castrate-Resistant Prostate Cancer; mCRPC (Metastatic Castration-resistant Prostate Cancer)
Sites: Jinan, China; Shanghai, China
- Study of XNW5004 Tablets in Advanced Prostate CancerPivotal-lookingNot yet recruiting
Evopoint Biosciences Inc.Industry
NCT07730580 · 242 participants (planned) · Start Jul 13, 2026 · Primary completion Dec 31, 2028
Drug: XNW5004 1200 mg BID in Combination with Abiraterone plus Prednisone; XNW5004 1200 mg BID in Combination with Docetaxel plus Prednisone and 5 more · For: Advanced Prostate Cancer
Evopoint Biosciences Inc.Industry
NCT07730515 · 176 participants (planned) · Start Aug 15, 2025 · Primary completion Sep 30, 2028
Drug: XNW5004 combined with CHOP (incremental); XNW5004 combined with CHOEP (incremental) and 2 more · For: Non-hodgkin Lymphoma; Peripheral T-cell Lymphoma
Sites: Shanghai, China
Evopoint Biosciences Inc.Industry
NCT06558513 · 120 participants · Start Aug 3, 2021 · Primary completion Aug 30, 2025
Drug: XNW5004 tablets · For: Advanced Tumor; Lymphoma
Sites: Tianjin, China
- A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell LymphomaPivotal-lookingRecruiting
Evopoint Biosciences Inc.Industry
NCT06776952 · 120 participants (planned) · Start Apr 10, 2025 · Primary completion Jan 2028
Drug: XNW5004 ; Chidamide placebo; XNW5004 placebo; Chidamide · For: Relapsed/Refractory Peripheral T Cell Lymphoma
Sites: Beijing, China
- Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular LymphomaRecruiting
Evopoint Biosciences Inc.Industry
NCT07545603 · 65 participants (planned) · Start Feb 14, 2026 · Primary completion Dec 31, 2027
Drug: XNW5004 tablets · For: Follicular Lymphoma, Grade 1; Follicular Lymphoma, Grade 2; Follicular Lymphoma, Grade 3 and 1 more
Sites: Beijing, China
- To Evaluate XNW5004 Tablets in Patients with Relapsed or Refractory Peripheral T Cell LymphomaNot yet recruiting
Evopoint Biosciences Inc.Industry
NCT06702605 · 50 participants (planned) · Start Nov 2024 · Primary completion Jan 2027
Drug: XNW5004 tablets · For: Relapsed/Refractory Peripheral T Cell Lymphoma
Evopoint Biosciences Inc.Industry
NCT06022757 · 12 participants · Start Sep 20, 2023 · Primary completion Jan 13, 2025
Drug: XNW5004; KEYTRUDA® (pembrolizumab) 25 mg/mL Solution for Injection · For: Carcinoma; Squamous Cell Carcinoma of Head and Neck; Urothelial Carcinoma and 5 more
Sites: Guangzhou, China
Newest research
PubMed records naming it or its code names, newest first.
- DOT1L shapes ncPRC1 target gene repression to maintain germinal center B-cell identity in diffuse large B-cell lymphoma.
Göbel C, Niccolai R, Gregoricchio S, et al. · Blood 2026
- Unveiling the New Trick for Epigenetic Drug: Radiation Enhancement of Prostate Cancer by the EZH2 Inhibitor Tazemetostat.
Du TQ, Ou Y, Liu RJ, et al. · J Cell Mol Med 2026
- Discovery of XNW5004 as a novel EZH2 inhibitor that enhances anti-tumor immunity and synergizes with PD-1 blockade immunotherapy in lung adenocarcinoma.
Lin Z, Ma W, Sun H, et al. · J Transl Med 2026
- NRF1 predominantly causes EZH2 overexpression in cancer cells.
Qiao J, Liu Z, Gu L, et al. · Cell Death Dis 2026
- Targeting Wnt/β-catenin and circadian regulator restores PRC2/EZH2-controlled chromatin bivalency and suppresses cell state diversity.
Yang Y, Zhang X, Venkadakrishnan VB, et al. · J Clin Invest 2026
- Biological Evaluation of a Novel Compound with Predicted EZH2 and EED Binding Against Human Malignant Melanoma Cells.
Gorbunov S, Kyriakou S, Anestopoulos I, et al. · Int J Mol Sci 2026
Also in development for Relapsed/Refractory Peripheral T Cell Lymphoma
- TucidinostatChidamide, HBI-8000Phase 39 trials
Chipscreen Biosciences, Ltd. · Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy, Unresectable or Metastatic Melanoma, Progressive Brain Metastasis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.